191 related articles for article (PubMed ID: 16524647)
1. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates.
Mascarell L; Bauche C; Fayolle C; Diop OM; Dupuy M; Nougarede N; Perraut R; Ladant D; Leclerc C
Vaccine; 2006 Apr; 24(17):3490-9. PubMed ID: 16524647
[TBL] [Abstract][Full Text] [Related]
2. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
3. Induction of anti-Tat neutralizing antibodies by the CyaA vector targeting dendritic cells: influence of the insertion site and of the delivery of multicopies of the dominant Tat B-cell epitope.
Fayolle C; Davi M; Dong H; Ritzel D; Le Page A; Knipping F; Majlessi L; Ladant D; Leclerc C
Vaccine; 2010 Oct; 28(42):6930-41. PubMed ID: 20728521
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.
Fanales-Belasio E; Moretti S; Fiorelli V; Tripiciano A; Pavone Cossut MR; Scoglio A; Collacchi B; Nappi F; Macchia I; Bellino S; Francavilla V; Caputo A; Barillari G; Magnani M; Laguardia ME; Cafaro A; Titti F; Monini P; Ensoli F; Ensoli B
J Immunol; 2009 Mar; 182(5):2888-97. PubMed ID: 19234184
[TBL] [Abstract][Full Text] [Related]
5. Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
Turbant S; Martinon F; Moine G; Le Grand R; Léonetti M
Vaccine; 2009 Aug; 27(39):5349-56. PubMed ID: 19607953
[TBL] [Abstract][Full Text] [Related]
6. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.
Gavioli R; Cellini S; Castaldello A; Voltan R; Gallerani E; Gagliardoni F; Fortini C; Cofano EB; Triulzi C; Cafaro A; Srivastava I; Barnett S; Caputo A; Ensoli B
Vaccine; 2008 Jan; 26(5):727-37. PubMed ID: 18096278
[TBL] [Abstract][Full Text] [Related]
7. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination.
Castaldello A; Brocca-Cofano E; Voltan R; Triulzi C; Altavilla G; Laus M; Sparnacci K; Ballestri M; Tondelli L; Fortini C; Gavioli R; Ensoli B; Caputo A
Vaccine; 2006 Jul; 24(29-30):5655-69. PubMed ID: 16781023
[TBL] [Abstract][Full Text] [Related]
8. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.
Majlessi L; Simsova M; Jarvis Z; Brodin P; Rojas MJ; Bauche C; Nouzé C; Ladant D; Cole ST; Sebo P; Leclerc C
Infect Immun; 2006 Apr; 74(4):2128-37. PubMed ID: 16552042
[TBL] [Abstract][Full Text] [Related]
9. The binding affinity of double-stranded RNA motifs to HIV-1 Tat protein affects transactivation and the neutralizing capacity of anti-Tat antibodies elicited after intranasal immunization.
Partidos CD; Hoebeke J; Moreau E; Chaloin O; Tunis M; Belliard G; Briand JP; Desgranges C; Muller S
Eur J Immunol; 2005 May; 35(5):1521-9. PubMed ID: 15789358
[TBL] [Abstract][Full Text] [Related]
10. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine.
Ensoli B; Cafaro A
J Biol Regul Homeost Agents; 2000; 14(1):22-6. PubMed ID: 10763887
[TBL] [Abstract][Full Text] [Related]
11. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
[TBL] [Abstract][Full Text] [Related]
12. Erythrocytes deliver Tat to interferon-gamma-treated human dendritic cells for efficient initiation of specific type 1 immune responses in vitro.
Corinti S; Chiarantini L; Dominici S; Laguardia ME; Magnani M; Girolomoni G
J Leukoc Biol; 2002 Apr; 71(4):652-8. PubMed ID: 11927652
[TBL] [Abstract][Full Text] [Related]
13. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.
Hervas-Stubbs S; Majlessi L; Simsova M; Morova J; Rojas MJ; Nouzé C; Brodin P; Sebo P; Leclerc C
Infect Immun; 2006 Jun; 74(6):3396-407. PubMed ID: 16714570
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules.
Fraternale A; Paoletti MF; Dominici S; Buondelmonte C; Caputo A; Castaldello A; Tripiciano A; Cafaro A; Palamara AT; Sgarbanti R; Garaci E; Ensoli B; Magnani M
Vaccine; 2011 Sep; 29(40):6823-9. PubMed ID: 21816192
[TBL] [Abstract][Full Text] [Related]
15. Plant based HIV-1 vaccine candidate: Tat protein produced in spinach.
Karasev AV; Foulke S; Wellens C; Rich A; Shon KJ; Zwierzynski I; Hone D; Koprowski H; Reitz M
Vaccine; 2005 Mar; 23(15):1875-80. PubMed ID: 15734059
[TBL] [Abstract][Full Text] [Related]
16. A synthetic HIV-1 Tat protein breaches the skin barrier and elicits Tat-neutralizing antibodies and cellular immunity.
Partidos CD; Moreau E; Chaloin O; Tunis M; Briand JP; Desgranges C; Muller S
Eur J Immunol; 2004 Dec; 34(12):3723-31. PubMed ID: 15549730
[TBL] [Abstract][Full Text] [Related]
17. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat.
Caselli E; Betti M; Grossi MP; Balboni PG; Rossi C; Boarini C; Cafaro A; Barbanti-Brodano G; Ensoli B; Caputo A
J Immunol; 1999 May; 162(9):5631-8. PubMed ID: 10228047
[TBL] [Abstract][Full Text] [Related]
18. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates.
Wille-Reece U; Flynn BJ; Loré K; Koup RA; Kedl RM; Mattapallil JJ; Weiss WR; Roederer M; Seder RA
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15190-4. PubMed ID: 16219698
[TBL] [Abstract][Full Text] [Related]
19. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides.
Belliard G; Hurtrel B; Moreau E; Lafont BA; Monceaux V; Roques B; Desgranges C; Aubertin AM; Le Grand R; Muller S
Vaccine; 2005 Feb; 23(11):1399-407. PubMed ID: 15661389
[TBL] [Abstract][Full Text] [Related]
20. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
